Company intelligence
Viome PRO
Imagine a world where illness is optional.
About Viome PRO
Viome Life Sciences was founded in 2016 with a mission to make illness optional by predicting and preventing chronic diseases, cancers, and aging through a deeper understanding of an individual's biology at a molecular level. The Viome Pro division leverages proprietary RNA sequencing technology, exclusively licensed from Los Alamos National Laboratory, and AI to develop non-invasive early detection tests for high-mortality cancers and chronic diseases.
Verified activity
Signals from Viome PRO
3 published signals
Research & Knowledge
Viome PRO published a study in Nature examining the gut microbiome of patients with locally advanced rectal cancer.
Reported by Michael Bass, M.D.
Research & Knowledge
Viome PRO conducted a chat with Florence Comite about TPE and human exposure to microplastics.
Reported by Brad Younggren
Research & Knowledge
Viome PRO published a report titled Beyond the Scope: The Non-Invasive Revolution Reshaping Colorectal Cancer Screening by Scope Forward.
Reported by Michael Bass, M.D.